Nose drop vaccines aim to protect kids from RSV
NCT ID NCT03596801
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested two experimental RSV vaccines given as nose drops in 60 children. Some children already had RSV antibodies (ages 1-5) and some did not (ages 6 months-2 years). The main goals were to check safety and whether the vaccines triggered an immune response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University Center for Immunization Research
Baltimore, Maryland, 21205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Nasal spray vaccine aims to shield infants from RSV
- Could a simple pill tame RSV? new trial tests obeldesivir
- New swab test aims to spot COVID, flu, and RSV in minutes
- New device aims to detect flu, RSV, and COVID-19 in one quick test
- RSV drug trial for kids under 5 halted early – only 4 children enrolled
- Triple-Threat vaccine aims to shield seniors from three respiratory viruses